Advances in precision medicine

Next-generation gene-editing therapies are advancing in the clinic, but many companies in the field are early-stage, high-risk enterprises—not the profile that investors and pharma are seeking in today’s uncertain climate.

In conversation with Eric Esser, President and Chief Executive Officer, Telesis Bio

By detecting and targeting myeloid-dependent immune suppression, Bectas Therapeutics is on a mission to realize the full potential of cancer immunotherapies.

PROVIREX is developing first-in-class advanced therapies that may offer the chance of a cure for people with life-threatening persistent viral infections.

Bio-Sourcing is developing innovative solutions that combine cutting-edge gene-editing and nuclear-transfer technologies to up-scale the production of biopharmaceuticals while lowering carbon emissions and costs.

The clinical success of biologics is often hindered by a lack of safe, targeted delivery systems. SiVEC Biotechnologies aims to change this with its groundbreaking BactPac platform.